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Six years after the first Society guidelines were published, cryptococcal meningitis (CM) remains an important cause of 
morbidity and mortality among HIV-infected adults in South Africa. Several important developments have spurred the 
publication of updated guidelines to manage this common fungal opportunistic infection. Recommendations described here 
include: (1) screening and pre-emptive treatment; (2) laboratory diagnosis and monitoring; (3) management of a first episode 
of CM; (4) amphotericin B deoxycholate toxicity prevention, monitoring and management; (5) timing of antiretroviral therapy 
among patients with CM; (6) management of raised intracranial pressure; (7) management of relapse episodes of CM.
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Six years after the first Society guidelines were 
published,[1] cryptococcal meningitis (CM) 
remains an important cause of morbidity and 
mortality among HIV-infected adults in South 
Africa (SA).[2] Several important developments 
have spurred the publication of updated guidelines to manage 
this common opportunistic fungal infection. First, for the 
first time in December 2011, the World Health Organization 
(WHO) published a Rapid Advice guideline focused on the 
management of HIV-associated CM in resource-limited 
settings.[3] Second, cryptococcal screening, an old strategy 
that has been revisited to detect cryptococcal disease earlier 
and pre-emptively reduce mortality, is being implemented 
in a phased manner in SA[4] and is being considered in other 
African countries. Third, the diagnostic landscape for CM has 
changed with the introduction of a United States Food and 
Drug Administration (FDA)-approved cryptococcal antigen 
(CrAg) lateral flow assay (LFA), which is simple, accurate and 
useful as a point-of-care test.[5] Finally, several clinical trials, 
many undertaken in Southern Africa, have improved our 
understanding of issues such as which first-line antifungal 
regimens are best suited to a resource-limited setting,[6-9] when 
to start antiretroviral therapy (ART),[10,11] and how to safely 
administer amphotericin B deoxycholate,[12] which has been 
used by many more SA clinicians as first-line induction-phase 
treatment for CM in the last 5 years.[13] 
1.  Screening and pre-emptive 
treatment 
Refer to Table 1 for a summary of this recommendation.
1.1 Background
Early diagnosis of HIV infection and early initiation of ART 
before immunosuppression is the most important strategy to 
reduce the incidence of CM and associated mortality. In SA, 
patients should initiate ART according to the current national 
guidelines.[14,15] However, screening for early cryptococcal 
disease and pre-emptive antifungal treatment may be a useful 
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count among patients at the time of ART 
initiation remains low in SA.[16] The WHO, 
in their recently issued Rapid Advice 
guideline, indicated that routine screening 
for cryptococcal disease in ART-naive adults 
with a CD4+ T-lymphocyte count <100 cells/
µl may be considered prior to ART initiation 
in populations with a high prevalence of 
cryptococcal antigenaemia. [3] In two ART 
cohorts in SA, the prevalence of newly-
diagnosed antigenaemia among patients with 
a CD4+ T-lymphocyte count <100 cells/µl 
was 4% and 7%, respectively. [17] This is greater 
than the threshold above which screening 
was found to be potentially cost-saving in 
a Ugandan study. [18,19] To reduce disability 
and deaths associated with HIV infection, 
screening and pre-emptive antifungal treat-
ment of cryptococcal disease has been 
suggested for routine implementation as part 
of the South African National Strategic Plan 
for HIV, STIs and TB, 2012 - 2016.[4] Primary 
azole prophylaxis for cryptococcal disease, in 
the absence of a screening programme, is not 
routinely recommended by the WHO.[3]  
1.2 Detailed recommendations
1.2.1 Who to screen
HIV-infected adults with a CD4+ T-lympho-
cyte count <100 cells/µl are recommended to 
be screened for cryptococcal antigenaemia. If 
screening is initiated by a clinician (medical 
practitioner or nurse trained in nurse-initiated 
management of ART (NIMART)) and not 
performed reflexively in the laboratory, then 
the expert panel recommends that screening 
be restricted to: ART-naive adults with 
CD4+ T-lymphocyte count <100 cells/µl and 
no prior CM. Although ART-experienced 
patients with a CD4+ T-lymphocyte count that 
remains <100 cells/µl may also be at risk for 
cryptococcal disease,[20] there is insufficient 
current evidence to routinely recommend 
screening ART-ex perienced adults. There are 
also insufficient data to recommend routine 
cryptococcal screening of HIV-infected 
children and adolescents, among whom the 
incidence of CM is much lower.[3, 21] 
Table 1. Summary of recommendation 1: Screening and pre-emptive treatment 
Scenario Recommendations 
HIV-infected adults with 
CD4+ T-lymphocyte count 
<100 cells/µl
• Screen for cryptococcal antigenaemia on serum or plasma by reflex laboratory or clinician-initiated testing
• If clinician-initiated testing is performed, screening should be restricted to ART-naive adults with 
no prior CM
• Either the LA or LFA may be used as a screening test
HIV-infected children or 
adolescents 
• There are insufficient data to recommend screening in this population 
Patients with a positive 
CrAg test result
• Refer to Fig. 1 and recommendations 1, 3 and 5 regarding further investigations, antifungal treatment 
and timing of ART
• If ART was started before the CrAg-positive result was received, follow the algorithm in Fig. 1, continue 
ART and monitor the patient very carefully for symptoms and signs of cryptococcal IRIS 
Patients with a negative 
CrAg test result 
• Evaluate for other opportunistic infections and start ART as soon as possible 
ART = antiretroviral therapy; LA = cryptococcal latex agglutination test; LFA = cryptococcal lateral flow assay (dipstick); CrAg = cryptococcal antigen; 
IRIS = immune reconstitution inflammatory syndrome.
Cryptococcal antigen screening when




•  Contact patient for urgent follow-up
•  Screen for symptoms of meningitis*
•  Check for special situations†
Symptomatic Asymptomatic§
Amphotericin B plus fluconazole
800 mg daily for 2 weeks in hospital
Fluconazole 800 mg daily for
2 weeks as outpatient
Lumbar puncture (+) Lumbar puncture (-)
Fluconazole 400 mg daily for 2 months then 200 mg daily
Continue fluconazole for minimum of 1 year in total and discontinue when
patient has had 2 CD4 counts >200 cells/μl taken at least 6 months apart
Start ART after 4 - 6 weeks of
antifungal therapy
Start ART after 2 weeks of antifungal
therapy
Start fluconazole 1 200 mg daily and refer
immediately for lumbar puncture
Fig. 1 Screen-and-treat algorithm for ART-naive adult patients with a CD4+ T-lymphocyte count 
<100 cells/µl.
*  Symptomatic for meningitis if either of the following is present: headache; confusion. 
†  Special situations include: prior cryptococcal meningitis; pregnancy or breastfeeding mothers; clinical liver disease.
§  A lumbar puncture may be considered if available.







The most cost-effective screening strategy 
has not yet been defined. Reflex laboratory 
screening, where blood samples with a CD4+ 
T-lymphocyte count <100 cells/ µl are auto-
matically tested for CrAg, is being conducted 
at healthcare facilities in the Gauteng and 
Free State provinces in 2012/2013.[4] Screening 
initiated by clinicians is being conducted in 
other provinces such as the Western Cape.[4] 
Although the latex agglutination (LA) test has 
been more extensively evaluated for diagnosis 
of cryptococcal disease, the rapid LFA is equally 
valid as a screening test. The laboratory turn-
around time is short for the CrAg screening 
test; however, initiation of ART should not be 
delayed unnecessarily while waiting for CrAg 
test results. 
1.2.3  Management of CrAg-positive 
patients
The clinician should urgently evaluate CrAg-
positive patients for symptoms and signs 
of meningitis, including headache and 
confusion (Fig. 1). For the management of 
symptomatic CrAg-positive patients, refer 
to recommendations 3, 4, 5 and 6. Patients 
without symptoms of meningitis may be offer -
ed a lumbar puncture (LP), if this is immediately 
accessible, to exclude early asymptomatic CM. 
For patients without suspected meningitis, 
oral fluconazole (800 mg for 2 weeks) followed 
by standard consolidation and maintenance 
treatment  (refer to recommendation 3) is 
recommended; the same applies to patients 
with an LP that is cryptococcal test-negative. 
Among patients without signs or evidence of 
meningitis, ART is recommended to be started 
two weeks after antifungal therapy is initiated. 
As part of the screen-and-treat algorithm 
(Fig. 1), CrAg-positive patients also need to be 
evaluated for the following clinical situations: 
1.2.3.1 Prior CM
Patients with a history of CM do not need to be 
screened routinely as cerebrospinal fluid (CSF) 
and blood specimens may remain CrAg-positive 
for months to years. However, if a patient with 
prior CM is screened and found to be CrAg-
positive and has new symptoms or signs of 
meningitis, a full evaluation should be undertaken 
for relapse disease (refer to recommendations 
2 and 7). If the patient does not have new 
symptoms or signs of meningitis, the clinician 
should ensure that the patient has received or 
is receiving adequate fluconazole maintenance 
therapy (refer to recommendation 3). The serum/
plasma (and CSF) CrAg test can remain positive 
for a prolonged period after successful treatment; 
therefore, if these tests are positive in the absence 
of symptoms and signs, this is not an indication 
of relapse.
1.2.3.2 Pregnant/breastfeeding women
Fluconazole is teratogenic (category D).[22] 
Women of child-bearing age who screen CrAg-
positive should have a pregnancy test prior to 
starting fluconazole; those who are not pregnant 
and are started on fluconazole should be advised 
to avoid becoming pregnant during treatment. 
CrAg-positive patients who are pregnant 
should be offered an LP before a decision is 
made regarding management. If the patient has 
laboratory evidence of CM, then she should be 
treated for CM with amphotericin B. The risks, 
benefits and alternative to fluconazole treatment 
(i.e. ART and close clinical monitoring) should 
be discussed with the pregnant CrAg-positive 
patient without laboratory-confirmed CM and 
consultation with a medical practitioner who is 
experienced in the care of HIV-infected patients 
is recommended; in this context, consideration 
of factors such as the trimester and CrAg 
titre may be useful. For mothers who are 
breastfeeding, consultation with an experienced 
medical practitioner is also recommended as 
fluconazole can be transmitted in large amounts 
through breast milk to the infant.[22] 
1.2.3.3 Clinical liver disease
Patients with a history of liver disease or 
with evidence of clinical liver disease deserve 
careful monitoring because fluconazole may 
cause liver injury. Consultation with a medical 
practitioner who is experienced in the care of 
HIV-infected patients is recommended.
2.  Laboratory 
diagnosis and 
monitoring
Refer to Table 2 for a summary of this re-
commendation.
2.1 Background
Cryptococcus neoformans is the most commonly 
detected meningitis-causing pathogen in SA.[23] 
All adults with suspected meningitis should 
be investigated for CM. Patients with CM may 
present with fever as well as symptoms and 
signs related to inflamed meninges (including 
neck stiffness), raised intracranial pressure 
(including headache, confusion, altered level 
of consciousness, sixth cranial nerve palsies 
with diplopia and visual impairment, and 
papilloedema) and encephalitis (including 
memory loss and new-onset psychiatric 
symptoms).[24] Cutaneous lesions and pul-
monary involvement (including cavitation, 
nodular infiltrates and consolidation) may 
also occur. Symptomatic relapses are common 
and are most often a result of inadequate or 
premature cessation of maintenance flucona-
zole treatment. [25] The incidence of CM is much 
lower among children;[21] African children 
with CM may present with an acute onset of 
illness and focal neurological signs may be less 
common.[26] 
2.2 Detailed recommendations 
2.2.1 Diagnosis of first CM episode
LP is required to establish an aetiological 
diagnosis of suspected meningitis. LP may also 
alleviate symptoms – such as headache, altered 
level of consciousness, and sixth cranial nerve 
palsies – that are a direct result of raised 
intracranial pressure. For a suspected first 
episode of CM, CSF should be submitted to the 
laboratory for a rapid test (either India ink or 
CrAg test) and fungal culture. If the India ink 
test is performed as the only rapid test and is 
negative, the laboratory should then perform 
a CrAg test (either LA or LFA). The sensitivity 
and specificity of CrAg tests (LA and LFA) 
are higher than of India ink. [3] C. neoformans 
can be cultured within 72 hours from the 
CSF of patients with a first episode. There 
is no need to routinely order a baseline CSF 
CrAg titre; most patients are diagnosed when 
the CSF fungal burden is high and antifungal 
treatment for a first episode is standardised 
and not influenced by the CrAg titre (refer 
to recommendation 3). If laboratory facilities 
are unavailable, a point-of-care LFA may be 
performed on CSF at the bedside.[5,27] 
Antifungal susceptibility testing should 
not be requested for a first episode because 
antifungal drug minimum inhibitory 
concentrations (MICs) are invariably very 
low at first diagnosis[28] and, even if elevated, 
the relevance is difficult to interpret in this 
setting. If opening pressure was not measured 
at the time of the diagnostic LP, the LP 
should be repeated to measure the pressure 
once a diagnosis of CM is confirmed (refer 
to recommendation 6 for diagnosis and 
management of raised intracranial pressure).
2.2.2  Diagnosis of CM if focal 
neurological signs are 
present or if LP is not 
immediately available 
Focal neurological signs are relatively un-
common in CM, except for sixth cranial nerve 
palsy. Where focal neurological signs are 







Fig. 2. Laboratory procedure to set up and read the cryptococcal antigen lateral fl ow assay (Immuno-Mycologics, Norman, OK) (source: Immy CrAg LFA 
package insert; reprinted with permission).
Table 2. Summary of recommendation 2: Laboratory diagnosis and monitoring
Scenario Recommendations
Diagnosis of first episode of 
suspected CM 
• All adults with suspected meningitis should be investigated for CM
• An LP should be performed to obtain CSF
• CSF should be submitted to a laboratory for a rapid test (either India ink or CrAg test) and fungal culture
• If opening pressure was not measured at the time of diagnostic LP, LP should be repeated to measure the 
pressure once a diagnosis of CM is confirmed (refer to recommendation 6 for the management of raised 
intracranial pressure)
• The laboratory should routinely perform a CrAg test (either LA or LFA) when an India ink test is 
negative 
• If laboratory facilities are unavailable, a cryptococcal LFA may be performed at the bedside on 
drawing CSF 
• There is no need to routinely request a baseline CSF CrAg titre or antifungal susceptibility testing 
Diagnosis of CM if LP is not 
immediately available or focal 
neurological signs are present 
• Serum/plasma may be tested for CrAg to determine if the patient has disseminated cryptococcal disease 
• Patients with a positive serum/plasma CrAg test and symptoms and signs of meningitis should be 
empirically started on antifungal treatment (refer to recommendation 3) and referred to a centre where 
an LP and/or a CT brain scan can be performed  
Diagnosis of subsequent 
episode of suspected CM 
• A careful history should be taken and the patient should be assessed clinically for signs and symptoms 
of meningitis 
• An LP should be performed to obtain CSF
• Opening pressure should be measured (refer to recommendation 6 for the management of raised 
intracranial pressure) 
• CSF should be submitted to a laboratory for prolonged fungal culture (minimum 14 days) (note: India 
ink and CrAg tests are not useful for the diagnosis of subsequent episodes of CM as they can stay 
positive for a prolonged period despite successful treatment) 
• Antifungal susceptibility testing may be considered in selected circumstances (see below and refer to 
recommendation 7)
Monitoring response to 
antifungal treatment 
• Resolution of symptoms and signs can be used to monitor response to treatment 
• Unless there is a specific indication (e.g. persistent symptoms or signs suggesting late-onset raised 
intracranial pressure), LP should not be routinely performed after 14 days of antifungal treatment to 
document conversion of CSF from culture-positive to culture-negative* 
• CSF and serum/plasma CrAg titres should not be routinely monitored
Suspected antifungal drug-
resistant isolate 
• Consider antifungal susceptibility testing if a patient has had more than one relapse and the causes listed 
in Table 7 have been excluded (also refer to recommendation 7)
• Fluconazole MICs should be determined at an academic or reference laboratory and interpreted by an 
experienced clinical microbiologist in conjunction with clinical findings 
Screening for cryptococcal 
antigenaemia  
• Refer to recommendation 1
CM = cryptococcal meningitis; LP = lumbar puncture; CSF = cerebrospinal fluid; CrAg = cryptococcal antigen; LA = latex agglutination test; LFA = lateral flow assay; 
MIC = minimum inhibitory concentration. 
*If symptoms persist at or beyond 14 days, LP should be repeated to re-measure opening pressure, which may increase despite successful CSF sterilisation – refer to recommendation 6.






present, a CT brain scan should be performed 
first to exclude the presence of space-occupying 
lesions. If a CT brain scan cannot be performed 
immediately in the case of focal neurological 
signs, or if LP is not immediately available to 
make a diagnosis of meningitis, then serum/
plasma may be tested for CrAg to determine 
if the patient has disseminated cryptococcal 
disease. Patients with a positive serum/plasma 
CrAg test and symptoms and signs of meningitis 
are very likely to have CM and should be started 
empirically on antifungal treatment (refer to 
recommendation 3). Patients without focal 
neurological signs should then be referred to 
a centre where LP can be performed, while 
patients with focal neurological signs first need 
to have a computed tomography (CT) brain 
scan, followed by an LP (if this is not contra-
indicated by CT brain findings). Although aware 
that it may be difficult to access a CT brain scan 
in rural settings, the panel cannot recommend 
that an LP be performed in a patient with focal 
neurological signs without a scan. 
2.2.3  Diagnosis of a subsequent 
episode of CM
A careful history should be taken including 
dates of previous episodes of CM and the 
patient should be assessed clinically for 
signs and symptoms of meningitis. An LP is 
indicated if the patient has signs and symptoms 
of meningitis. CSF should be submitted for 
fungal culture with plates incubated for at least 
14 days to detect slow fungal growth. Rapid 
tests are not useful for diagnosis of subsequent 
episodes because both India ink and CrAg tests 
may remain positive for months to years even 
if treatment has been successful. Antifungal 
susceptibility testing may be considered in 
certain circumstances (see below and refer to 
recommendation 7). 
2.2.4  Monitoring response to 
treatment
Resolution of symptoms and signs should be 
used to monitor response to treatment. LP 
should not be routinely performed after 14 
days of antifungal treatment to document 
conversion of CSF from culture-positive to 
culture-negative, because the expert panel 
advises routinely changing from induction 
to consolidation phase treatment at 14 days. 
Given that the culture result takes several days 
(up to 14 days) to become available, the culture 
result will not affect the timing of this change. 
If symptoms persist at day 14, LP should be 
repeated to re-measure opening pressure, 
which may increase despite successful CSF 
sterilisation. Patients with raised intracranial 
pressure should be managed according to 
recommendation 6. CSF CrAg may remain 
positive for months to years and CrAg 
titres are not recommended to be routinely 
measured to monitor response to treatment. 
Serum/plasma CrAg titres are also not useful 
to monitor response to treatment.[29] 
2.2.5  Suspected antifungal drug-
resistant isolate
Antifungal susceptibility testing may be 
considered if the patient has had more than 
one relapse episode and the causes listed 
in Table 7 have been excluded. Isolates 
with elevated fluconazole MICs have been 
described occasionally from relapse episodes 
– especially where fluconazole monotherapy 
is initially given – and are unusual if 
amphotericin B-based induction treatment 
was administered during the first episode. As 
there are no established clinical breakpoints 
for C. neoformans and fluconazole, it is 
useful to test isolates from the initial and 
subsequent episodes in parallel at an academic 
or reference laboratory and document a four-
fold (double-dilution) change in MIC,[14,16] 
which may suggest resistance. This requires 
storage of the initial isolate, which may not 
always be possible at a diagnostic laboratory. 
MICs should be interpreted by an experienced 
clinical microbiologist, in conjunction with the 
clinical history. Refer to recommendation 7 for 
the management of patients with fluconazole-
resistant isolates. Non-susceptibility to ampho-
tericin B is very unusual and susceptibility 
testing to this drug should not be requested. 
3.  Management of 
first episode of CM
Refer to Table 3 for a summary of this re-
commen dation.
3.1 Detailed recommendations
The antifungal treatment of CM is divided 
into 3 phases: induction, consolidation and 
maintenance.
3.1.1 Induction phase (2 weeks)
Guidelines of the Infectious Disease Society of 
America (IDSA) and the WHO recommend 
the first choice for induction-phase treatment 
as: amphotericin B (0.7 - 1.0 mg/ kg/ dose) 
and flucytosine (100 mg/ kg/ day).[3,30] Unfor-
tunately, flucytosine is not currently available 
in Southern Africa. The panel supports 
international advocacy efforts to provide 
greater access to flucytosine in resource-
limited settings, particularly in light of the 
findings of a recently-published clinical trial 
in Vietnam showing improved survival among 
patients with CM treated with amphotericin B 
plus flucytosine v. amphotericin B alone.[9] 
In the absence of flucytosine, the expert 
panel advocates that Southern African patients 
should be treated with the following induction 
therapy for the first two weeks: amphotericin 
B deoxycholate (1 mg/kg/ day intravenous (IV) 
administration) plus flu conazole (800 mg per os 
(PO) daily). Among SA adults, the 1 mg/kg/day 
dose of amphotericin B is well tolerated. [31] The 
panel advises adding fluconazole (800 mg/ day) 
during the induction phase in line with the 
WHO guideline; this is supported by evidence 
from a clinical trial that this combination is 
associated with a marginally superior rate of 
CSF clearance compared with amphotericin B 
alone, and evidence from two trials showing 
a non-significant decrease in mortality and 
neurological morbidity.[3,6,9,32]
Table 3. Summary of recommendation 3: Management of first episode of CM
Phase Duration Treatment
Induction • 2 weeks • Amphotericin B (1 mg/kg/day IV) and 
fluconazole (800 mg daily PO)
Consolidation • 8 weeks • Fluconazole (400 mg daily PO)
Maintenance • Until the CD4+ T-lymphocyte count >200 cells/µl 
for 6 months on ART and most recent viral load is 
suppressed (minimum 10 months)
• Fluconazole (200 mg daily PO)
IV = intravenous; PO = per os.







Where amphotericin B is unavailable or 
cannot be given safely, the patient should be 
transferred to a hospital where amphotericin 
B is available. It is reasonable to give a 
fluconazole dose of 1 200 mg PO daily while 
transfer is awaited.
In countries where amphotericin B is 
unavailable, the panel would advise clinicians 
to follow the WHO guideline with respect 
to high-dose fluconazole options.[3] However, 
in SA, all patients diagnosed with CM 
should have access to amphotericin B-based 
induction-phase treatment.
 
3.1.2  Consolidation phase 
(further 8 weeks)
The panel recommends 400 mg fluconazole 
PO daily for 8 weeks.
3.1.3 Maintenance phase
This is also termed secondary prophylaxis. 
The panel recommends 200 mg fluconazole 
PO daily for at least a further 10 months (i.e. 
until at least 12 months after treatment for CM 
was started). Maintenance fluconazole should 
only be stopped when the CD4+ T-lymphocyte 
count is >200 cells/µl for at least 6 months and 
the most recent HIV-1 viral load is suppressed. 
Patients with CM should have 6-monthly CD4+ 
T-lymphocyte measurements until flu conazole 
can be stopped.
3.1.4 Adolescents and children
A dose of 1 mg/kg/ day amphotericin B 
should be prescribed during the induction 
phase. Fluconazole doses should also be 
calculated according to body weight. Induction 
phase: 12 mg/kg/day (up to 800 mg daily); 
consolidation phase: 6 - 12 mg/kg/day (up to 
400 mg daily); maintenance phase: 6 mg/kg/day 
(up to 200 mg daily).
3.1.5 Baseline renal impairment
If patients have renal impairment at the time 
of diagnosis, this is not a contraindication 
to receiving amphotericin B deoxycholate 
at the standard dose (i.e. 1 mg/kg/day); 
however, creatinine should be monitored 
frequently and if it deteriorates significantly, 
then amphotericin B may need to be stopped 
and treatment continued with fluconazole 
monotherapy. When used as monotherapy 
during induction, the fluconazole dose would 
be 1 200 mg daily with normal renal function. 
With a creatinine clearance of 10 - 50 ml/min, 
the dose of fluconazole used as monotherapy 
should be reduced by 50% to 600 mg daily, 
and if creatinine clearance is <10 ml/ min, 
fluconazole should be reduced to 400 mg daily. 
If the baseline renal impairment is thought 
to be due to dehydration, then intensive IV 
rehydration efforts should occur while starting 
amphotericin B. For the prevention, monitoring 
and management of renal impairment that 
develops during amphotericin B deoxycholate 
administration, refer to recommendation 4. 
3.1.6  Patients receiving TB 
treatment
In contrast to previous guidelines, the panel 
does not recommend a fluconazole dose 
increase in patients receiving rifampicin, as 
the induction of fluconazole metabolism by 
rifampicin causes only moderate reductions 
in fluconazole exposure,[33] and because of 
the high doses of fluconazole that are initially 
being used.
3.1.7  Adjunctive corticosteroid 
therapy
The panel does not currently recommend 
adjunctive corticosteroid therapy in the initial 
management of CM. There is an ongoing 
international clinical trial that aims to address 
this question.[34] Refer to recommendation 
7 for the use of corticosteroids in patients 
with immune inflammatory reconstitution 
syndrome (IRIS). 
3.1.8 Immunological failure on ART
In patients who develop immunological 
failure while receiving ART and where the 
CD4+ T-lymphocyte count drops <200 cells/µl 
after secondary prophylaxis has been stopped, 
the panel advises restarting fluconazole at 
200 mg daily. Refer to the above section on 
maintenance-phase treatment for the duration 
of treatment. 
3.1.9  Non-adherence to 
maintenance treatment
In patients who stop taking fluconazole 
maintenance prematurely and then return for 
care but are asymptomatic, the panel advises 
simply restarting fluconazole (200 mg daily) 
and monitoring closely for the recurrence 
of meningitis. Refer to the above section on 
maintenance-phase treatment for the duration 
of treatment.
3.1.10 Analgesia
Therapeutic LP is the best form of ‘analgesia’ 
for headaches associated with raised intra-
cranial pressure. Paracetamol can be used, 
but not non-steroidal anti-inflammatory 
drugs (NSAIDs), due to the nephrotoxicity 
concern with amphotericin B deoxycholate. 
Morphine may also be appropriate and is 
not contraindicated in the presence of raised 
intracranial pressure. 




Refer to Table 4 for a summary of this re-
commendation. 
4.1 Background
Major adverse effects of amphotericin B 
deoxycholate include renal impairment 
due to renal tubular toxicity (usually in the 
second week of therapy), hypokalaemia, 
hypomagnesaemia, anaemia, febrile reactions 
and chemical phlebitis. Nephrotoxicity and 
electrolyte abnormalities may be prevented 
by pre-hydration, by avoiding concurrent 
use of other nephrotoxins (e.g. NSAIDs 
and aminoglycosides) and by routine 
administration of potassium and magnesium 
supplements. Phlebitis is very common 
in patients receiving amphotericin B and 
increases the risk of localised cellulitis as well 
as sepsis. Anaemia commonly occurs among 
patients receiving amphotericin B and can 
be clinically significant, particularly among 
those with a low baseline haemoglobin level. 
Haemoglobin decreases >2 g/dl occurred in 
50 - 71% of patients over 2 weeks of treatment 
in an SA trial.[7] It is important also to exclude 
other treatable causes of anaemia and consider 
transfusion in symptomatic patients. 
4.2  Detailed recommendations 
4.2.1  Administration of 
amphotericin B deoxycholate
Amphotericin B deoxycholate powder (50 mg 
vials) should be refrigerated between 2oC and 
8oC and protected from light.[35] The total daily 
dose of amphotericin B is calculated based 
on a dose of 1 mg/kg/day; amphotericin B 
deoxycholate powder from each 50 mg vial 
should be aseptically reconstituted in 10 ml 
of sterile water. The calculated volume of the 
concentrate (i.e. reconstituted drug in sterile 
water) should be injected into a 1 litre bag 
of 5% dextrose water and shaken to mix. 
Amphotericin B deoxycholate should never 
be mixed with normal saline or half-normal 
saline as it will precipitate. Once mixed, the 
solution (≤0.1 mg amphotericin B per 1 ml 






5% dextrose water for infusion through a 
peripheral IV line[22]) must be infused within 
24 hours of preparation or discarded. A test 
dose is not recommended.[3] Protection from 
light with a brown bag is unnecessary.[35] The 
line that is used for amphotericin B infusion 
should not be used to administer other drugs 
simultaneously. The solution should be infused 
over 4 hours or more (infusion over <4 hours 
can result in cardiac complications). Once the 
infusion is complete, the line should be flushed 
with normal saline.
4.2.2  Prevention of amphotericin B 
deoxycholate-related toxicities
Patients should be pre-hydrated with 1 litre 
of normal saline containing 1 ampoule of 
potassium chloride (20 mmol K+ per 10 ml 
ampoule) infused over 2 hours before adminis-
tration of amphotericin B deoxycholate. This 
reduces renal toxicity and hypokalaemia. 
Patients should be given 1 200 mg of pota ssium 
chloride twice daily (equivalent to 16 mmol of 
oral potassium, e.g. two Slow-K 600 mg tablets 
twice daily, 8 mmol K+ per tablet) and up to 
one 500 mg magnesium chloride daily (e.g. two 
Slow-Mag 535 mg tablets daily, 5.33 mmol Mg2+ 
per tablet) for the duration of treatment with 
amphotericin B deoxycholate. Routine pre-
emptive potassium supplementation should 
not be given to patients with pre-existing 
renal impairment or hyperkalaemia. To mini-
mise the risk of phlebitis, lines should be 
flushed with normal saline after amphotericin B 
infusion is complete. The empty bag should not 
be left attached to the IV line. The IV line should 
be removed if the patient develops a fever after 
the infusion, or at the first sign of redness or 
discomfort at the insertion site. Febrile reactions 
may occur; to prevent recurrence, the infusion 
should be administered at a slow rate over the 
first half-hour while observing the patient 
closely, as treatment such as paracetamol may 
be required. 
4.2.3  Clinical and laboratory 
monitoring 
At minimum, for the duration of amphotericin 
B deoxycholate treatment, baseline and twice-
weekly monitoring of serum creatinine and 
potassium, and baseline and weekly monitoring 
of haemoglobin are recommended. Renal 
toxicity is more likely to develop in the second 
week of treatment. Fluid input and output 
should be monitored carefully. Chemical 
phlebitis is often complicated by infection 
at the IV line insertion site, which can result 
in bacteraemia; the insertion site should be 
monitored by regular clinical examination, and 
febrile patients with a suspected insertion site 
infection should be appropriately investigated 
and managed.
4.2.4 Management of toxicities
For patients with significant hypokalaemia 
(serum K+ <3.3 mmol/l), IV replacement is 
required: 2 ampoules of potassium chloride 
(20 mmol K+ per 10 ml ampoule) in 1 litre 
of normal saline 8-hourly. Among those who 
develop hypokalaemia, serum potassium 
should be monitored daily until resolved. 
If hypokalaemia remains uncorrected, 
serum magnesium should be checked (if 
this test is available) and/or oral magnesium 
supplementation doubled. IV magnesium 
sulphate may be considered for persistent 
hypokalaemia and hypomagnesaemia. If 
serum creatinine doubles from baseline, 
one dose of amphotericin B deoxycholate 
may be omitted and/or pre-hydration may 
be increased to 1 litre of normal saline 
8-hourly; serum creatinine should then be 
monitored daily. If serum creatinine improves, 
amphotericin B may be restarted at a dose of 
Table 4. Summary of recommendation 4: Amphotericin B toxicity prevention, monitoring and management
Scenario Recommendations
Administration of amphotericin B  
deoxycholate* 
• Amphotericin B powder should be reconstituted in sterile water; inject the calculated volume 
of reconstituted drug in water into 1 litre of 5% dextrose water and administer within 24 hours 
• Amphotericin B can be administered via peripheral IV line if the solution contains ≤0.1 mg 
amphotericin B in 1 ml of 5% dextrose water
• A test dose is unnecessary 
• The solution should be infused over at least 4 hours 
Prevention of amphotericin B 
deoxycholate-related toxicities 
• Patients should be pre-hydrated with 1 litre of normal saline containing 1 ampoule of 
potassium chloride (20 mmol) infused over 2 hours before the amphotericin B infusion†
• Twice-daily oral potassium and daily oral magnesium supplementation should be 
administered (adults)
• To minimise the risk of phlebitis, lines should be flushed with normal saline after 
amphotericin B infusion is complete and the infusion bag should not be left attached to the IV 
administration set after infusion is complete
Monitoring • Baseline and twice-weekly creatinine and potassium (and magnesium, if available)
• Baseline and weekly haemoglobin
• Fluid input and output monitoring 
Management of toxicities • If creatinine doubles, then 1 dose of amphotericin B may be omitted or pre-hydration can 
be increased to to 1 litre 8-hourly. If creatinine remains elevated or repeatedly rises, then 
amphotericin B should be stopped and fluconazole used as suggested in recommendation 3 
(baseline renal impairment section).
• Febrile reactions can be treated with paracetamol (1 g) 30 minutes before infusion (if severe, 
hydrocortisone (25 mg IV) can be given before subsequent infusions)
IV = intravenous.
* For adolescents and children, drugs should be calculated by body weight. 
†   For children and adolescents, normal saline, with 1 ampoule of potassium chloride (20 mmol) added per litre of fluid, should be infused at 10 - 15 ml/kg over 2 - 4 hours (not more than 1 litre) prior 
to amphotericin B administration. If saline is unavailable, then other parenteral rehydration solutions, e.g. Darrow’s solution or Ringer’s lactate that already contain potassium can be used.







0.7 mg/kg/day and alternate-day treatment 
could be considered. If creatinine remains 
elevated or repeatedly rises, amphotericin B 
should be stopped and fluconazole used as 
suggested in recommendation 3 (baseline 
renal impairment section). If febrile reactions 
occur, paracetamol (1 g) may be given 
30 minutes before infusion, or for severe 
reactions, hydrocortisone (25 mg IV) can be 
administered before subsequent infusions.[22] 
5.  Timing of ART 
among patients 
with CM
Refer to Table 5 for a summary of this re-
commendation.
5.1 Detailed recommendations
All HIV-infected patients who are diagnosed 
with CM are eligible for co-trimoxazole 
preventative therapy and ART. 
The panel recommends commencing 
ART 4 - 6 weeks after CM diagnosis, and 
strongly advises that ART not be delayed 
beyond 6 weeks after diagnosis; some panel 
members advise that clinicians should aim 
to start exactly 4 weeks after diagnosis of 
CM. Although most patients with CM have 
advanced immuno suppression with very low 
CD4+ T-lymphocyte counts, two randomised 
clinical trials in sub-Saharan Africa have 
shown excess early mortality when ART was 
commenced while patients were still receiving 
induction-phase treatment for CM.[10,11] In the 
latter trial, conducted in Uganda and SA, 
patients who started ART 1 - 2 weeks after CM 
diagnosis had a 15% higher mortality rate than 
those who deferred ART until 5 - 6 weeks.[11] 
Another small trial showed possible excess 
IRIS in those patients who started early.[36]
The long in-hospital stay associated with 
amphotericin B therapy should be utilised 
for pre-ART counselling, identification of a 
treatment supporter and early referral to an 
ART clinic. Clinicians should aim to set up an 
ART clinic appointment within one week of 
discharge from hospital; this prevents delays in 
ART initiation beyond what is advised in this 
guideline. Patients initiated on ART should 
be counselled regarding the risk of developing 
IRIS. If a patient is referred to another facility 
for ART, then the need for fluconazole 
maintenance therapy should be communicated. 
The panel recommends standard first-line 
ART regimens among patients with CM.[14,15] 
If nephrotoxicity occurred on amphotericin 
B, the renal function should be checked 
before starting ART to ensure that it has 
improved (creatinine clearance >60 ml/ min) 
before commencing tenofovir. There are 
potential interactions between nevirapine 
and fluconazole, but studies have shown that 
these interactions do not affect the efficacy or 
toxicity of therapy.[37,38] The panel recommends 
checking ALT if symptoms of hepatitis or 
jaundice develop while patients are receiving 
fluconazole, but routine alanine transaminase 
(ALT) monitoring is not indicated.
The panel advises that, among patients 
who present with relapse of CM or a first 
CM episode after defaulting ART, ART is also 
restarted after 4 - 6 weeks. 
One situation where ART may be delayed 
further is if a patient is still symptomatic with 
headaches at the visit when ART is due to 
be started. In such a situation, an LP should 
be repeated to measure pressure and fungal 
culture should be used to exclude persistent 
culture-positivity. ART should be deferred 
and such patients may require further LPs or 
amphotericin B therapy to ensure control of 
symptoms before starting ART.
Among patients who are serum/plasma 
CrAg-positive on screening, but do not have 
symptoms of meningitis and thus do not have 
an LP performed or have an LP that excludes 
CM, the panel advises starting ART 2 weeks 
after starting fluconazole (Fig. 1).
6.  Management of 
raised intracranial 
pressure
Refer to Table 6 for a summary of this re-
commendation.
6.1 Background
Raised intracranial pressure occurs in ≤75% 
of patients with CM and is thought to result 
from obstruction of CSF outflow, resulting 
in build-up of CSF pressure.[39] It may be 
present at diagnosis of CM or develop while 
the patient is receiving treatment. It may cause 
severe headaches, vomiting, confusion or a 
depressed level of consciousness, ophthalmo-
plegia (particularly sixth cranial nerve palsies) 
and visual disturbance/loss. Clinicians need to 
consider raised intracranial pressure as part 
of the differential diagnosis and act appro-
Table 5. Summary of recommendation 5: Timing of ART among patients with CM
Recommendations 
• Start ART 4 - 6 weeks after diagnosis of CM. The panel strongly advises that ART not be delayed beyond 6 weeks after diagnosis; some 
members of the panel advise that clinicians should aim to initiate ART exactly 4 weeks after diagnosis of CM.
• No adjustment in first-line ART regimen is required for patients who are ART-naive (unless renal dysfunction precludes the use of 
tenofovir).
Table 6. Summary of recommendation 6: Management of raised intracranial pressure
Recommendations
• Measure baseline opening pressure
• If opening pressure >25 cm H2O, remove 10 - 30 ml of CSF 
• Repeat LP whenever there are symptoms or signs of raised intracranial pressure (headache, vomiting, drowsiness, confusion, 
sixth cranial nerve palsy, visual disturbance)
• Daily therapeutic LPs may be required
 
CSF = cerebrospinal fluid; LP = lumbar puncture.






priately if a patient exhibits these symptoms 
or signs at any stage of CM management. To 
alleviate raised pressure, therapeutic LPs are 
indicated. New-onset hypertension may be 
a sign of increased intracranial pressure (i.e. 
Cushing’s triad) and should prompt an LP 
to measure opening pressure instead of anti-
hypertensive medications.
6.2 Detailed recommendations
It is good practice to measure the CSF opening 
pressure whenever a diagnostic LP is done. 
However, in practice the opening pressure will 
not have been measured at the initial diagnostic 
LP in CM. Thus, once the diagnosis of CM is 
made, an LP should be repeated to measure CSF 
opening pressure, particularly if the patient still 
has a headache (which is usually the case). The 
pressure should be measured with the patient 
lying down and without excessive spinal flexion. 
If the opening pressure is raised (>25 cm H2O), 
then 10 - 30 ml of CSF should be drained 
(to normalise pressure to <20 cm H2O or 
decrease the pressure by at least 50% – based 
on repeat measurements of closing pressure). 
Thereafter, the need for pressure relief should 
be dictated by the recurrence of symptoms 
of raised intracranial pressure. Patients may 
require daily LPs. Patients with raised intra-
cranial pressure experience considerable 
relief of symptoms following therapeutic LPs. 
Approximately 15% of patients with initially 
normal intracranial pressure will develop 
raised intracranial pressure during treatment; 
therefore, all patients should be monitored 
daily for headache or signs of raised pressure 
that should prompt an LP.
Patients with persistent pressure symptoms 
and who fail to respond to serial lumbar 
punctures may require lumbar drain insertion 
or shunting procedures. Neurosurgical consul-
tation should be sought.
In situations where manometers are not 
available, the panel suggests using a central 
venous pressure set manometer and 
attaching this to the LP needle using aseptic 
technique. In situations where this is also 
unavailable, if there are symptoms or signs 
of raised intracranial pressure due to CM 
(severe headache, drowsiness, sixth cranial 
nerve palsies), then the panel recommends 
performing an LP and removing 20 ml of CSF 
and repeating daily, if necessary.
Manometers can be ordered from Rocket Medical 
PLC (Tyne and Wear, UK) through Summit 
Surgical (Gauteng) (email: phil@acroteq.co.za or 
jim@wycliffe.edu; fax: +27 (0)86 565 6347). 
7.  Management of 
relapse episodes 
of CM
There are several possible reasons for the 
recurrence of symptoms of meningitis in 
patients treated for CM. In certain cases, 
recurrence is due to microbiological relapse, 
but situations exist where there is symptom 
recurrence but CSF fungal cultures are 
negative. The causes are summarised in Table 7. 
When a patient presents with a recurrence, 
it is not always possible immediately to be sure 
of the aetiology. Assessment should include:
• Assessment of adherence to fluconazole 
consolidation and maintenance-phase 
treatment (self-reported and pharmacy 
refill data)
• To support an IRIS diagnosis, an enquiry as 
to whether the patient recently started ART
• An LP to measure opening pressure, assess 
CSF inflammation and for a prolonged 
fungal culture (14 days) – there is no 
role for India ink staining or CSF/serum/
plasma CrAg assays in establishing the 
cause of recurrence, as these may remain 
positive for months (years even) in 
patients after successful treatment (refer to 
recommendation 2)
• If the CSF is culture-positive and non-
adherence does not appear to be the cause, 
then fluconazole susceptibility testing should 
be considered (refer to recommendation 2) 
and should be performed in a reference 
laboratory; the panel recom mends this 
especially when there has been more than 
one relapse, despite reported good adherence.
If the cause of the recurrence is attributed 
to non-adherence, then the patient should be 
treated as for the first episode. The reasons for 
non-adherence should be explored and the 
patient should receive additional adherence 
counselling, preferably with a treatment 
supporter. If the patient also defaulted ART, 
this should be re-initiated 4 - 6 weeks after 
presentation. ART may need to be adjusted if 
there is concern that there has been virological 
failure on first-line ART.
Paradoxical cryptococcal IRIS occurs 
among patients treated for cryptococcal 
disease who start ART and develop a recur-
rence or worsening of the clinical manifest-
ations of cryptococcal disease. IRIS is thought 
to be the result of an immuno pathological 
reaction directed at residual cryptococcal 
antigen at sites of the disease. [40] IRIS occurs, 
on average, 6 weeks after ART is commenced, 
but delayed cases (even more than a year 
after ART initiation) are described.[41] IRIS 
affects approximately 20% of patients with 
cryptococcal disease who start ART, and 
mortality may be substantial. [42] The most 
frequent manifestation is a recurrence of 
the symptoms of meningitis, often with 
raised intracranial pressure. Typically, 
the CSF fungal culture is negative at the 
time of IRIS presentation; IRIS represents 
Table 7. Possible causes of recurrent symptoms and signs of meningitis in CM
• Non-adherence to fluconazole consolidation or maintenance treatment 
• Non-adherence to ART 
• Paradoxical IRIS
• ‘Breakthrough’ of C. neoformans growth in CSF without laboratory evidence of resistance
• Ongoing raised intracranial pressure without one of the above (i.e. isolated mechanical problem)
• Virological failure on ART after having stopped fluconazole maintenance treatment 
• Resistance to fluconazole (this is uncommon if amphotericin B induction therapy is used)
• Other diagnoses (e.g. TB meningitis)
 
ART = antiretroviral therapy; CSF = cerebrospinal fluid; IRIS = immune reconstitution inflammatory syndrome; TB = tuberculosis.







an immunological reaction rather than a 
microbiological recurrence. However, in 
cases where induction therapy was recent 
(<2 months), the CSF fungal culture may 
still be positive. Other cryptococcal IRIS 
manifestations include lymphadenitis and 
cryptococcomas.[40] 
In all patients with suspected paradoxical 
CM IRIS, an LP should be performed to 
measure pressure and obtain a fungal culture 
incubated for up to 14 days. It is not possible 
to make a diagnosis of IRIS with certainty 
prior to excluding microbiological relapse 
on CSF fungal culture. If the symptoms 
are mild, the panel recommends performing 
therapeutic LPs if there is raised intracranial 
pressure, providing analgesia and increasing 
the fluconazole dose to 1 200 mg daily with 
regular review and follow-up of the CSF 
fungal culture result. If the CSF fungal culture 
is negative, the dose of fluconazole can be 
reduced back to what it was (400 mg or 200 mg 
daily depending on the timing of the CM IRIS 
event). If patients with suspected CM IRIS 
have severe symptoms or deteriorate with 
the approach above, the panel recommends 
treating with amphotericin B (1 mg/kg/day 
IV) plus fluconazole (800 mg PO daily) until 
the CSF culture is confirmed as negative. 
If the CSF culture is still negative after 7 
days of  incubation, amphotericin B can 
be stopped. If the fungal culture is positive 
by 7 days, then amphotericin B should be 
continued for 14 days. Daily therapeutic LPs 
may be required if the opening pressure is 
raised. A CT head scan should be considered, 
as mass lesions and cerebral oedema can 
occur with IRIS. Analgesia should be 
provided. For patients with severe IRIS who 
do not respond to the above treatment, 
corticosteroids (e.g. prednisone 1mg/kg/
day PO or dexamethasone IV) should be 
considered. The panel recommends that 
corticosteroids preferably be used among 
patients with IRIS who are documented to be 
CSF fungal culture-negative and when other 
aetiologies are excluded; however, if there 
is life-threatening neurological deterioration, 
corticosteroids should be started immediately.
In patients with CM due to fluconazole-
resistant isolates, subsequent management 
should be discussed with a medical 
practitioner experienced in the treatment of 
CM. Such patients should receive induction 
therapy with amphotericin B again. 
Consolidation and maintenance options 
depend on the fluconazole MIC and include 
high-dose fluconazole with or without weekly 
amphotericin B infusions or voriconazole.
In patients with multiple relapses, it is 
important to document the conversion of 
CSF from culture-positive to culture-negative 
before stopping amphotericin B. Such cases 
should be discussed with an experienced 
medical practitioner and fluconazole suscepti-
bility testing should be performed (refer to 
recommendation 2).
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